Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer
Masayuki Takeda, Kazuko Sakai, Masato Terashima, Hiroyasu Kaneda, Hidetoshi Hayashi, Kumiko Tanaka, Kentaro Okamoto, Takayuki Takahama, Teruhiko Yoshida, Tsutomu Iwasa, Tsuneo Shimizu, Yoshikane Nonagase, Kenichiro Kudo, Shuta Tomida, Tetsuya Mitsudomi, Kazumasa Saigo(Medical Genetics Center), Akihiko Ito(Kindai University), Kazuhiko Nakagawa, Kazuto Nishio(Kindai University)
Cited by 81Open Access
Abstract
Related Papers
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al.|New England Journal of Medicine|2004|11.5k
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William Pao, Vincent A. Miller, Maureen F. Zakowski et al.|Proceedings of the National Academy of Sciences|2004|4.3k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou et al.|Journal of Clinical Oncology|2012|1.6k